Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating emicizumab every 4 weeks in adults and children with Hemophilia A has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-12-26